

# **30-Day Countdown – Phase III, Lift 2:** Retirement of the Transition Policy for Beneficiaries 22 Years of Age and Older

March 21, 2023

### What Pharmacy Providers and Prescribers Need to Know

On April 21, 2023, Phase III, Lift 2 (P3/L2) will be implemented, lifting the Transition Policy for 17 Standard Therapeutic Classes (STCs). This is the second in a series of lifts to retire or phase out the grandfathering of historical prior authorizations (PAs) and claims by lifting the override of **NCPDP Reject Code 75 – Prior Authorization Required**.

The following 17 STCs will be impacted with implementation of P3/L2 on April 21, 2023:

Phase III, Lift 2 (P3/L2) Drug Classes *			
Contraceptives and	Ophthalmic, Nasal,	Thyroid Agents	Topical Anesthetic
Hormones	and Otic Preparations	(STC 55, 57)	Agents
(STC 59 – 64)	(STC 19, 20)		(STC 45)
Dermatologic Agents	Biologic Agents	Glucocorticoids and	Anti-Parkinson's
(STC 93, 95)	(STC 90)	Corticotropins	(STC 9)
		(STC 50, 51)	

\* STC refers to the Standard Therapeutic Classification number.

- Beneficiaries 21 years of age and younger are exempt from Phase III: Retirement of the Transition Policy.
- Enteral nutrition products for beneficiaries of all ages are also exempt from Phase III: Retirement of the Transition Policy.

## What Pharmacy Providers and Prescribers Need to Do

If a beneficiary is currently receiving a medication in the STCs identified for P3/L2 as listed in the table above, pharmacy providers and prescribers should prepare for the retirement of the Transition Policy in the following ways:

- 1. Consider covered therapies that may not require a PA, if clinically appropriate. Review the following:
  - Medi-Cal Rx Contract Drugs Lists & Covered Products Lists
  - Medi-Cal Rx Approved NDC List
  - Prescribers: Refer to your ePrescribing application.
- 2. If a change in therapy is not appropriate, submit a PA request via one of the approved Medi-Cal Rx Submission Methods:
  - <u>CoverMyMeds</u>®
  - Medi-Cal Rx Secured Provider Portal
  - NCPDP P4 Transaction
  - Fax
  - U.S. Mail

### Resources

- For more information about Medi-Cal Rx Reinstatement, visit the <u>Medi-Cal Rx Education &</u> <u>Outreach</u> page on the <u>Medi-Cal Rx Web Portal</u> and select **Medi-Cal Rx Reinstatement**.
- Review the <u>Medi-Cal Rx Reinstatement of Prior Authorizations and Retirement of the</u> <u>Transition Policy: Phases II, III, and IV</u> slide deck.
- Review <u>Medi-Cal Rx Phased Reinstatement Frequently Asked Questions (FAQs)</u>.
- Review the <u>Medi-Cal Rx Reinstatement Phases II–III</u> webinar recording.
- Review the <u>30-Day Countdown Phase III, Lift 1: Retirement of the Transition Policy for</u> <u>Beneficiaries 22 Years of Age and Older</u> alert.
- Refer to the <u>Medi-Cal Rx Bulletins & News</u> and <u>Medi-Cal Rx Forms & Information</u> pages of the <u>Medi-Cal Rx Web Portal</u> for guidance to successfully submit PAs.

## **Contact Information**

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at <u>MediCalRxEducationOutreach@magellanhealth.com</u>.